• Company
• New oHCM drug 'Camzyos' is under review for reimb list
• by Eo, Yun-Ho Aug 2, 2024 05:51am

• Company
• VUNO knocks on the U.S. market to generate operating profit
• by Hwang, Byung-woo Aug 1, 2024 05:48am

• Company
• Celltrion’s Steqeyma approved in CAN…targets Stelara mkt
• by Hwang, Byung-woo Aug 1, 2024 05:48am

• Company
• Will the cardiomyopathy drug Vyndamax be reimb this time?
• by Eo, Yun-Ho Aug 1, 2024 05:48am

• Opinion
• [Reporter’s View] More legislation needed for CSO reporting
• by Lee, Jeong-Hwan Aug 1, 2024 05:48am

• Company
• Kim Sang-pyo, appointed as Moderna Korea's new GM
• by Eo, Yun-Ho Aug 1, 2024 05:47am

• Company
• Combination cancer immunotherapies show high synergy
• by Son, Hyung-Min Aug 1, 2024 05:47am

• Company
• Commercialization of global RSV vaccines in progress in KOR
• by Son, Hyung-Min Jul 31, 2024 05:52am

• Policy
• Approval of abortion drugs at a halt in KOR
• by Lee, Jeong-Hwan Jul 31, 2024 05:52am

• Company
• Competition rises in 1st-line urothelial cell carcinoma mkt
• by Eo, Yun-Ho Jul 31, 2024 05:51am